Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

NP-G2-044

Generic Name: NP-G2-044

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₆F_₃N_₃O_₂

CAS Number: 1807454-59-6

Unique Ingredient Identifier: 1ER2O3UZ4W

Overview

NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).

Background

NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Phase 1

Recruiting

Posted: 2021/08/26

Sponsor:Novita Pharmaceutica...

ID:NCT05023486

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Phase 1

Completed

Posted: 2017/06/27

Sponsor:Novita Pharmaceutica...

ID:NCT03199586

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Novita's Fascin Inhibitor NP-G2-044 Shows Promising Results in Phase 2 Trial for Advanced Solid Tumors

a month ago

Novita Pharmaceuticals' first-in-class fascin inhibitor NP-G2-044 demonstrated a 21% objective response rate and 76% disease control rate in patients with advanced solid tumors resistant to prior anti-PD-1 therapy.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy